New CKM guideline urges team-based care, yet UH data show major therapy gaps; CINEMA model boosts outcomes amid cost, trust, and handoff hurdles.
|Articles|December 1, 2000
Supplements and Featured Publications
- The Latest Clinical Advances in Antimicrobial Use -- A Managed Care Perspective
- Volume 6
- Issue 23 Suppl
Guidelines for the Management of Community-Acquired Pneumonia
Author(s)Richard E. Chaisson, MD
Advertisement
Articles in this issue
almost 26 years ago
Participating Facultyalmost 26 years ago
Introductionalmost 26 years ago
Clinical Choices of Antibiotics: Judging Judicious Usealmost 26 years ago
Is Drug Resistance Affecting Treatment Outcomes?almost 26 years ago
Optimizing the Use of Antimicrobial Therapyalmost 26 years ago
Selected Abstractsalmost 26 years ago
Continuing Medical Education QuizAdvertisement
Related to this article
Obesity care surges with GLP-1 demand, but fragmented ownership, prior authorizations, and coverage rules stall treatment—pharmacists step in.
Roundtables reveal HFpEF/HFmrEF care lags despite rising cases; learn new SGLT2/MRA strategies, screening, and scalable team pathways.
Simple operational changes are proving more effective at closing gaps in cardiovascular-kidney-metabolic (CKM) syndrome care than education campaigns alone, according to panelists at at Population Health Roundtable
Panelists at AJMC roundtables in Philadelphia, Boston, Washington, DC, and Chicago traced why atopic dermatitis stays undertreated despite new therapies.
Eye care access for underserved patients with diabetes is limited and poorly understood. We identified barriers and innovative solutions to improve overall care and establish evidence-based practices.
Patient understanding should be treated as a measurable equity outcome, not an assumed byproduct of care.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
4
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
5